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A 66-year-old female presented with a 1-month history of 
dyspepsia. An initial upper gastrointestinal endoscopy with 
biopsy revealed a low-grade mucosa-associated lymphoid 
tissue (MALT) lymphoma. A rapid urease test was positive for 
Helicobacter pylori. Endoscopic ultrasound (EUS) and com-
puted tomography (CT) revealed a 30×15-mm lymph node 
(LN) in the subcarinal area. Histopathologic and phenotypic 
analyses of the biopsy specimens obtained by EUS-guided 
ﬁ  ne-needle aspiration revealed a MALT lymphoma, and the 
patient was diagnosed with a stage 4E gastric MALT lym-
phoma. One year after H. pylori eradication, the lesion had 
disappeared, as demonstrated by endoscopy with biopsy, CT, 
fusion whole-body positron emission tomography, and EUS. 
Here, we describe a patient with gastric MALT lymphoma that 
metastasized to the mediastinal LN and regressed following 
H. pylori eradication. (Gut Liver 2012;6:270-274)
Key Words: Marginal zone B-cell lymphoma; Stomach
INTRODUCTION
The most common primary lymphoma of the gastrointestinal 
(GI) tract is mucosa-associated lymphoid tissue (MALT) lym-
phoma.
1 Although 90% of gastric MALT lymphomas are related 
to the presence of Helicobacter pylori,
2 areas other than the GI 
tract may be affected. We describe here a patient with gastric 
MALT lymphoma that metastasized to the mediastinal lymph 
node (LN) and regressed following H. pylori eradication. 
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CASE REPORT
A 66-year-old female presented with a 1-month history of 
dyspepsia. An initial upper GI endoscopy showed a shallow 
ulcerative lesion in the gastric high body and a hyperemic le-
sion in the low body (Fig. 1A). A rapid urease test was positive 
for H. pylori. Histologic sections of the high and low bodies 
showed patchy infiltration of small lymphocytes into the lamina 
propria and lymphoepithelial lesions; the lymphocytes were fo-
cally aggressive toward the gland (Fig. 1B). Phenotypic analysis 
showed that the lesion was positive for CD20, but negative for 
CD3, CD5, CD10, and Bcl-6, and that its proliferation rate was 
<2%, as shown by MIB1 (Ki-67) antibody analysis. Based on 
these histopathological and phenotypic features, the patient 
was diagnosed with low-grade MALT lymphoma. Staging pro-
cedures were performed. Endoscopic ultrasound (EUS) revealed 
hypoechoic disruption of the mucosal and submucosal layers; 
moreover, the fourth layer was preserved and there was no 
evidence of locoregional lymphadenopathy (u-T1smN0) (Fig. 
1C). A computed tomography (CT) scan showed a huge LN, 
about 30×15 mm in size, in the subcarinal area (Fig. 1D). Fu-
sion whole body positron emission tomography (PET) showed a 
hypermetabolic lesion, suggestive of a malignant lesion, on the 
subcarinal area. (Fig. 1E). Bone marrow biopsy findings were 
normal. EUS of the subcarinal lesion showed 32×12 mm LN. 
Histopathological and phenotypic analysis of a biopsy sample 
obtained by EUS-guided fine needle aspiration (Fig. 1F) showed 
that the lesion was a MALT lymphoma (Fig. 1G). The patient 
was diagnosed with a stage 4E gastric MALT lymphoma. For H. 
pylori eradication, the patient was treated with a 14-day course 
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and pantoprazole 80 mg a day. 
An endoscopy performed 2 months after treatment showed 
that the gastric high and low bodies were pale and flat, with 
no evidence of lymphoma infiltration (Fig. 2A and C). EUS of 
the subcarinal area and CT showed that the LN had decreased 
markedly in size, to 12×11 mm (Fig. 2E and G). Follow-up PET 
showed no significantly abnormal hypermetabolic lesions (Fig. 
2I). 
One year after treatment, all assessments, including endos-
copy with biopsy, CT, PET, and EUS, showed normal results 
(Fig. 2B, D, F, H and J). At present, 14 months later, the patient 
remains in complete remission.
DISCUSSION
More than 90% of gastric lymphomas are related to the pres-
ence of H. pylori; hence, eradication of H. pylori is the favored 
initial treatment for patients with early-stage H. pylori-positive 
gastric MALT lymphoma.
2 
However, the association between extragastric MALT lym-
phoma and H. pylori is not clear. Although several case reports 
have described the regression of extragastric MALT lymphomas 
after H. pylori eradication,
3,4 one study showed that the majority 
of patients with extragastric MALT lymphoma did not benefit 
from H. pylori eradication.
5 
In addition, there have been a few case reports showing that 
H. pylori eradication has led to the regression of advanced gas-
tric MALT lymphomas simultaneously involving two or more 
organs other than the stomach.
6,7 Recirculation of H. pylori - 
specific T-cells from the stomach to other organs via the blood 
or lymphatic system may trigger an inflammatory response in 
other MALT-lymphoma containing organs.
3,4,6,7 Alternatively, 
abnormal cells may spread from the stomach to other organs 
via the blood or lymphatic system.
5,8 
H. pylori eradication may also lead to the regression of sec-
ondarily involved perigastric LN and bone marrow. However, 
our patient was different, in that H. pylori eradication led to the 
regression of a mediastinal LN.
Fig. 1. Initial diagnostic tests. (A) Initial upper gastrointestinal endoscopy displaying a shallow ulcerative lesion in the gastric high body and a 
hyperemic lesion in the gastric low body. (B) Histopathologic examination of a gastric biopsy specimen displaying patchy infiltration of small 
lymphocytes and lymphoepithelial lesions in the lamina propria, which suggest the existence of a mucosa-associated lymphoid tissue (MALT) 
lymphoma (H&E stain, ×400). (C) Endoscopic ultrasound (EUS) analysis displaying hypoechoic disruption of the mucosal and submucosal layers. (D) 
Computed tomography scan displaying a 30×15 mm lymph node (LN) in the subcarinal area. (E) Positron emission tomography analysis display-
ing a hypermetabolic lesion suggestive of a malignant lesion in the subcarinal area. (F) EUS analysis of the subcarinal lesion revealing a 32×12 
mm LN. (G) Histopathologic examination of LN tissue, with the patchy infiltration of small lymphocytes, suggesting a MALT lymphoma (H&E 
stain, ×400).272  Gut and Liver, Vol. 6, No. 2, April 2012
The treatment for advanced gastric MALT lymphoma has not 
been clearly defined. Treatment is usually similar to that for 
patients with other advanced-stage indolent non-Hodgkin lym-
phoma.
9 Our findings, however, indicate that H. pylori eradica-
tion should be the first treatment in patients presenting with H. 
pylori-associated advanced gastric MALT lymphoma. Further 
molecular characterization of these tumors is necessary to deter-
mine the most suitable therapeutic strategy. 
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Fig. 2. Follow-up evaluations 2 mon-
ths (A, C, E, G, I) and 1 year (B, D, 
F, H, J) after Helicobacter pylori 
eradication. (A, C) Upper gastrointes-
tinal endoscopy, displaying pale, flat 
gastric high and low bodies without 
lymphoma infiltration (H&E stain, 
×400). (E, G) Endoscopic ultrasound 
and computed tomography scans 
of the subcarinal area, displaying a 
markedly smaller lymph node, sized 
12×11 mm. (I) Positron emission 
tomography analysis displaying no 
significantly abnormal hypermeta-
bolic lesions. (B, D, F, H, J) All find-
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